Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Journal	Cardiovascular Drugs and Therapy
DOIs	https://doi.org/10.1007/s10557-018-6830-x
State	Accepted/In press - Jan 1 2018

ASJC Scopus subject areas

Pharmacology
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1007/s10557-018-6830-x

Other files and links

Cite this

@article{fef4c641a2a64dfeb89f04bd4304dd64,

title = "Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?",

author = "Rosa Ahn and Vinay Prasad",

year = "2018",

month = jan,

day = "1",

doi = "10.1007/s10557-018-6830-x",

language = "English (US)",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

AU - Ahn, Rosa

AU - Prasad, Vinay

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85053713290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053713290&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6830-x

DO - 10.1007/s10557-018-6830-x

M3 - Article

C2 - 30232657

AN - SCOPUS:85053713290

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

ER -